Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia

International Clinical Psychopharmacology

Volumn 19, Issue 5, 2004, Pages 281-289

  Kasper, Siegfried ^a,c   Brecher, Martin ^b   Fitton, Lesley ^b   Jones, Andrew Martin ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atypical antipsychotics; Long term therapy; Quetiapine; Schizophrenia

Indexed keywords

QUETIAPINE;

AGITATION; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; LONG TERM CARE; MALE; MENTAL DISEASE; ORTHOSTATIC HYPOTENSION; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4344678568     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000138822.62874.fd     Document Type: Article

References (45)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
2. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association.
3. Andreasen N (1984). Modified Scale for the Assessment of Negative Symptoms. NIMH Treatment Strategies in Schizophrenia Study. Washington, DC: Department of Health and Human Services, Public Health Administration.
4. Andreasen NC (1995). Symptoms, signs, and diagnosis of schizophrenia. Lancet 346:477-481.
5. Arvanitis LA, Miller BG (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 study group. Biol Psychiatry 42:233-246.
6. Arvanitis LA, Rak IW (1997). The long-term efficacy and safety of 'Seroquel' (quetiapine). Schizophr Res 24:196-197.
7. Barnes TR, McPhillips MA (1999). Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry 38:34-43.
8. Bilder RM (1997). Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 42:255-264.
9. Borison RL, Arvanitis LA, Miller BG (1996). ICI, 204, 636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. The US Seroquel study group. J Clin Psychopharmacol 16:158-159.
10. Brecher M, Rak IW, Melvin K, Jones AM (2000). The long-term effect of quetiapine (Seroquel™) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 4:287-291.
11. Collaborative Working Group on Clinical Trial Evaluations (1998). Evaluating the effects of antipsychotics on cognition in schizophrenia. J Clin Psychiatry 59:35-40.
12. Colonna L, Saleem P, Dondey-Nouvel L, Rein W (2000). Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 15:13-22.
13. Csernansky JG, Mahmoud R, Brenner R (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16-22.
14. Copolov DL, Link CG, Kowalcyk B (2000). A multicentre, double-blind, randomised comparison of quetiapine (ICI 204, 636,'Seroquel') and haloperidol in schizophrenia. Psychol Med 30:95-105.
15. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S (2003). Olanzapine for schizophrenia. Cochrane Database Syst Rev 1:CD001359.
16. 1A receptors in human post-mortem brain. Eur J Pharmacol 386:313-315.
17. Emsley RA, Raniwalla J, Bailey PJ, Jones AM (2000). A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 15:121-31.
18. Goldstein JM (1996). In: Holliday SG, Ancill R, MacEwan G (editors): Breaking Down the Barriers. London: John Wiley & Sons Ltd, pp. 177-207.
19. Guy W (editor) (1976). AIMS: Abnormal Involuntary Movement scale. In: ECDEU Assessment Manual for Psychopharmacology, rev. edn (ADM 76-338). Rockville, MD US: Department of Health, Education and Welfare, pp. 534-535.
20. Guy W, Bonato R (editors) (1970). CGI: Clinical Global Impressions. Manual for the ECDEU Assessment Battery 2, rev. edn. Chevy Chase, MD: National Institute of Mental Health.
21. Hellewell JS, Haddad PM (2001). Differing tolerability profiles among atypical antipsychotics. Am J Psychiatry 158:501-502.
22. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R (2002). A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 63:516-523.
23. Hoge SK, Appelbaum PS, Lawlor T, Beck JC, Litman R, Greer A, et al. (1990). A prospective multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry 47:949-956.
24. Howard R, Rabins PV, Seeman MV, Jeste DV (2000). Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry 157:172-178.
25. Jablensky A (1995). Schizophrenia: the epidemiological horizon. In: Hirsch SR, Weinberger DR (editors): Schizophrenia. Oxford: Blackwell, pp. 206-252.
26. Jibson MD, Tandon R (1995). The negative symptoms of schizophrenia. Direct Psychiatry 15:1-7.
27. Jibson MD, Tandon R (1998). New atypical antipsychotic medications. J Psychiatr Res 32:215-228.
28. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 158:3.
29. Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S (1999). Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 249:83-89.
30. Kasper S, Tauscher J, Heiden A (2001). Quetiapine: efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol 11:S405-S413.
31. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
32. King DJ, Link CG, Kowalcyk B (1998). A comparison of bid and tid dose regiments of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology (Berl) 137:139-146.
33. Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S (1998). The development of treatment resistance in patients with schizophrenia: a clinical and pathological perspective. J Clin Psychopharmacol 18:20S-24S.
34. Möller HJ, Gagiano CA, Addington DE, Von Knorring L, Torres-Plank JF, Gaussares C (1998). Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. Int Clin Psychopharmacol 13:99-106.
35. Mullen J, Jibson MD, Sweitzer D (2001). A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23:1839-1854.
36. Nemeroff CB (1997). Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 58:45-49.
37. Overall J, Gorham D (1962). The brief psychiatric rating scale. Psychol Rep 10:799-812.
38. Sajatovic M, Ramirez LF (2003). Rating Scales in Mental Health, 2nd edn. Hudson, Ohio: Lexi-Comp.
39. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19.
40. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG (1997). Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54:549-557.
41. Stanniland C, Taylor D (2000). Tolerability of atypical antipsychotics Drug Saf 22:195-214.
42. Tauscher-Wisniewski S, Tauscher J, Jones C, Daskalakis ZD, Papatheodorou G, Epstein I et al. (2001) Quetiapine is an effective antipsychotic in first episode schizophrenia despite only transiently high dopamine-2 receptor blockade. Poster Presented at the Meeting of American College of Neuropsychopharmacology, Hawaii. Waikoloa: ACNP.
43. Tran PV, Tollefson GD, Sanger TM, Lu Y, Berg PH, Beasley CM Jr (1999). Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. Br J Psychiatry 174:15-22.
44. Van Putten T (1974). Why do schizophrenic patients fail to take their drugs? Arch Gen Psychiatry 31:67-72.
45. Whitworth AD, Fleischhacker WW (1995). Adverse events and antipsychotic drugs. Int Clin Psychopharmacol 9:21-27.